Ipsen’s history and milestones

Our History

90 years of expertise working in areas of high unmet medical need.

Founded in 1929 as a family business, Ipsen has almost a century of experience and expertise and focuses in three therapeutic areas: Oncology, Rare Disease and Neuroscience.


Ipsen’s Milestones


March 2023

Ipsen acquires Albireo

Ipsen acquires rare liver disease specialist Albireo, bringing into its portfolio Bylvay® (odevixibat), a non-systemic ileal bile acid transport inhibitor for the treatment of pediatric patients with pruritus in progressive familial intrahepatic cholestasis (PFIC).

August 2022

Epizyme acquired

Ipsen successfully completed the acquisition of Epizyme and its lead medicine, Tazverik®(tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor for adults with relapsed or refractory follicular lymphoma (FL), which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020. As part of the transaction, Ipsen also acquired Epizyme’s first-in-class, oral SETD2 inhibitor development candidate.

July 2022

Consumer HealthCare divested

In February 2022, Ipsen announced the proposed sale of the Consumer HealthCare (CHC) division after entering into exclusive negotiations with the French laboratory Mayoly Spindler. In July, Ipsen completed the divestment of the CHC business to Mayoly Spindler.


Boosting Ipsen’s capacities in Rare Disease

Ipsen acquired Montreal-based Clementia Pharmaceuticals, specializing in rare bone diseases, Clementia brought a drug candidate, palovarotene, to Ipsen for a rare genetic disease, fibrodysplasia ossificans progressiva (FOP).


Treatment approvals and asset acquisitions

The Dysport Injection was approved in the United States for the treatment of lower limb spasticity in children aged two years and older. Ipsen also licensed cabozantinib from Exelixis, which received marketing authorization the same year for the second-line treatment of advanced renal cell carcinoma. In January the following year, Ipsen announced the acquisition of certain assets of Merrimack Pharmaceuticals, including Onivyde®, for the treatment of pancreatic and ovarian cancer.

Scroll to load more loader